Css LLC Cardiff Oncology, Inc. Transaction History

Css LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $6,046 - $12,602	3,926 Added 12.27%	35,920 $55,000
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $33,338 - $114,550	15,800 Added 97.57%	31,994 $79,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $87,770 - $132,794	-17,519 Reduced 51.97%	16,194 $108,000
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $224,191 - $338,478	33,713 New	33,713 $224,000
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $81,490 - $175,249	-8,955 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $107,639 - $221,278	8,955 New	8,955 $161,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.